Strategy
Stages
Pre-IPOPublic
Sectors
Biotechnology
Geographies
Greenwich, Connecticut, USA
Recent changes
- Sep 6, 2026Sep 6, 2026Stages updated: Pre-IPO, Public deeptrackcapital.com
- Sep 5, 2026Sep 5, 2026Sectors updated: Biotechnology deeptrackcapital.com
Portfolio
2 totalCo-Investors
12Ascenta Capital · 1 sharedAtlas Venture · 1 sharedCormorant Asset Management · 1 sharedEcoR1 Capital · 1 sharedFidelity Investments · 1 sharedFrazier Life Sciences · 1 sharedGoldman Sachs Alternatives · 1 sharedIllumina Ventures · 1 sharedNextech Invest · 1 sharedSanofi Ventures · 1 sharedvenBio Partners · 1 sharedViking Global Investors · 1 shared
Similar Firms
overlapping sector, stage or regionLatest Pulse
- Sep 3, 2026Superluminal Raises $60M for AI-Designed Obesity PillThe Boston biotech's Series B, backed by Nvidia and Eli Lilly among others, funds Phase 1 trials of an oral MC4R agonist for rare genetic obesity designed by its de novo drug-discovery AI platform.→
- Aug 5, 2026Goldman-Backed Attovia Prices IPO, Lists on NasdaqAttovia Therapeutics priced its IPO at $17/share, raising roughly $212.5M, and began trading on Nasdaq today under ATTO -- another test of whether biotech's IPO window is genuinely reopening.→
- Jul 29, 2026Goldman-Backed Attovia Seeks $212.5M in Biotech IPOAttovia Therapeutics is seeking up to $212.5 million in a US IPO, offering 12.5 million shares at $15-$17 each, backed by Goldman Sachs Alternatives, Deep Track Capital, Frazier Life Sciences, and venBio.→
Deep Track Capital FAQ
What companies has Deep Track Capital invested in?
Deep Track Capital's portfolio includes Attovia Therapeutics, Triveni Bio.
Who does Deep Track Capital co-invest with most?
In the rounds Value Add tracks, Deep Track Capital most often invests alongside Ascenta Capital (1 shared deal), Atlas Venture (1 shared deal), Cormorant Asset Management (1 shared deal), EcoR1 Capital (1 shared deal), Fidelity Investments (1 shared deal).